

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

23 Jun 2026

### Evaluating the effect of Metformin administration on pregnancy outcomes in healthy overweight pregnant women

#### Protocol summary

##### Study aim

Main goal: Evaluating the effect of Metformin administration on pregnancy outcomes in healthy overweight pregnant women specific goals: 1. comparing the frequency of GDM between the main and control groups 2. comparing the frequency of fetal macrosomia between the main and control groups 3. comparing the frequency of preeclampsia between the main and control groups 4. comparing the frequency of abnormal gestational weight gain between the main and control groups 5. comparing the frequency of neonatal hypoglycemia between the main and control groups 6. comparing the frequency of neonatal mortality between the main and control groups

##### Design

This double blinded RCT will enroll subjects and controls (n:170; 170), administering metformin (1gr/day) and placebo, until delivery.

##### Settings and conduct

The main and control (n:170; 170) group will receive metformin (1gr/day) and placebo, respectively, until delivery. At GA: 24-28w, patients will undergo an oral glucose (75gr) challenge test. Estimated birth weight and growth percentile will be assessed twice (GA:32-34 & 37w). Gestational weight gain and the incidence of preeclampsia, fetal hypoglycemia, fetal death and birth defects will also be recorded.

##### Participants/Inclusion and exclusion criteria

All pregnant mothers (GA:12-16 weeks; Singleton;  $25 \leq \text{BMI} < 30$ ) visiting perinatology clinics of Motahari Hospital will be invited to participate. Those with a history of any general medical condition (e.g. DM, Hepatic disorders, hypertension) will be excluded.

##### Intervention groups

The main and control (n:170; 170) group will receive metformin (1gr/day) and placebo, respectively.

##### Main outcome variables

Incidence of fetal macrosomia  
Incidence of Gestational diabetes mellitus  
Incidence of preeclampsia

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20190716044229N1**

Registration date: **2020-02-06, 1398/11/17**

Registration timing: **registered\_while\_recruiting**

Last update: **2020-02-06, 1398/11/17**

Update count: **0**

##### Registration date

2020-02-06, 1398/11/17

##### Registrant information

##### Name

Samira Esmaili

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 44 3367 9124

##### Email address

samiraesmaili2019@yahoo.com

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2019-07-16, 1398/04/25

##### Expected recruitment end date

2020-03-19, 1398/12/29

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

Evaluating the effect of Metformin administration on pregnancy outcomes in healthy overweight pregnant women

**Public title**

Impact of metformin on pregnancy outcomes in overweight women

**Purpose**

Prevention

**Inclusion/Exclusion criteria****Inclusion criteria:**

Maternal age  $\geq 16$  years Singelton pregnancy Body mass index:  $25 \leq \text{BMI} < 30$  Negative history of Diabetes Mellitus Negative history of previous medical conditions Gestational age between 12 & 16 weeks

**Exclusion criteria:**

Multiple gestation Positive history of general medical conditions (e.g. diabetes)  $\text{BMI} < 25$  or  $\geq 30$

**Age**

From **16 years** old

**Gender**

Female

**Phase**

3

**Groups that have been masked**

- Participant
- Care provider
- Outcome assessor
- Data analyser

**Sample size**

Target sample size: **350**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

Block randomization will be performed by an epidemiologist, via employing specialized software. Blocks A and B, each, shall only include patients form the intervention or control groups.

**Blinding (investigator's opinion)**

Double blinded

**Blinding description**

At the start of the study, each patient will be assigned an individual code, which will be used for identification thereafter. These codes will be also be used for randomization and shall only be available and accessible to the individual in charge of coding and grouping the subjects. Intervention and control groups will remain unrevealed to both physician and patient until the conclusion of the study.

**Placebo**

Used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ethics committee of Urmia University of Medical Sciences

**Street address**

Orjhans Street, Resalat Blvd, Urmia , Iran

**City**

Urmia

**Province**

West Azarbaijan

**Postal code**

57147833

**Approval date**

2019-07-16, 1398/04/25

**Ethics committee reference number**

IR.UMSU.REC.1398.143

**Health conditions studied****1****Description of health condition studied**

Pregnancy outcomes in overweight pregnancies

**ICD-10 code****ICD-10 code description****Primary outcomes****1****Description**

Frequency of fetal macrosomia

**Timepoint**

Post-partum

**Method of measurement**

Neonatal weighing scale

**2****Description**

Incidence of gestational diabetes mellitus

**Timepoint**

From gestational age 24 weeks onward

**Method of measurement**

Three hour glucose tolerance test

**3****Description**

Incidence of preeclampsia

**Timepoint**

From gestational age 20 weeks onward

**Method of measurement**

Measurement of blood pressure and relevant laboratory analyses

## 4

### Description

Gestational weight gain monitoring

### Timepoint

From baseline until delivery

### Method of measurement

Weighing scale

## Secondary outcomes

empty

## Intervention groups

### 1

#### Description

Intervention group: oral metformin 500 mg/twice a day, (manufactured in Iran) from 12-16 week until delivery

#### Category

Prevention

### 2

#### Description

Control group: placebo with chemical composition: (Starch 200mg/Cellulose acetate 150 mg/Hypromellose 50mg/Sodium lauryl sulfate 50mg/Manesium stearate 50mg). Round and white in Metformin size. construction of Urmia School of Pharmacy. Laboratory of Pharmaceuticals. twice a day from 12-16 week until delivery.

#### Category

Placebo

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Motahari hospital

##### Full name of responsible person

Shabnam vazifekhah

##### Street address

Kosar center (Department of obstetrics and perinatolgy), Motahari Hospital, Kashani st.

##### City

Urmia

##### Province

West Azarbaijan

##### Postal code

51147

##### Phone

+98 44 3232 7077

##### Email

samiraesmaili2019@yahoo.com

##### Web page address

<https://motahari.umsu.ac.ir/>

## Sponsors / Funding sources

### 1

#### Sponsor

##### Name of organization / entity

Oroumia University of Medical Sciences

##### Full name of responsible person

Dr. Iraj Mohebbi

##### Street address

Orjans Street. Resalat Blvt, Urmia, Iran

##### City

urmia

##### Province

West Azarbaijan

##### Postal code

571478334

##### Phone

+98 44 3232 7077

##### Email

samiraesmaili2019@yahoo.com

##### Web page address

<https://motahari.umsu.ac.ir/>

#### Grant name

#### Grant code / Reference number

#### Is the source of funding the same sponsor organization/entity?

Yes

#### Title of funding source

Oroumia University of Medical Sciences

#### Proportion provided by this source

100

#### Public or private sector

Public

#### Domestic or foreign origin

Domestic

#### Category of foreign source of funding

empty

#### Country of origin

#### Type of organization providing the funding

Academic

## Person responsible for general inquiries

#### Contact

##### Name of organization / entity

Oroumia University of Medical Sciences

##### Full name of responsible person

Samira Esmaili

##### Position

Resident of Obstetrics & Gynecology

##### Latest degree

Medical doctor

##### Other areas of specialty/work

Gynecology and Obstetrics

##### Street address

Motahari Hospital, Kashani Street

##### City

Urmia

##### Province

West Azarbaijan

##### Postal code

04412234125

**Phone**

+98 44 3232 7077

**Email**

samiraesmaili2019@yahoo.com

**Web page address**

<https://motahari.umsu.ac.ir/>

## Person responsible for scientific inquiries

**Contact**

**Name of organization / entity**

Oroumia University of Medical Sciences

**Full name of responsible person**

Samira Esmaili

**Position**

Resident of Obstetrics & Gynecology

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Gynecology and Obstetrics

**Street address**

Kashani street, Motahari Hospital

**City**

Urmia

**Province**

West Azarbaijan

**Postal code**

04412234125

**Phone**

+98 44 3232 7077

**Email**

samiraesmaili2019@yahoo.com

**Web page address**

<https://motahari.umsu.ac.ir/>

## Person responsible for updating data

**Contact**

**Name of organization / entity**

Oroumia University of Medical Sciences

**Full name of responsible person**

Samira Smaili

**Position**

Resident of Obstetrics & Gynecology

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Gynecology and Obstetrics

**Street address**

Kashani St, Motahari Hospital

**City**

Urmia

**Province**

West Azarbaijan

**Postal code**

04412237077

**Phone**

+98 44 3232 7077

**Email**

samiraesmaili2019@yahoo.com

**Web page address**

<https://motahari.umsu.ac.ir/>

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

**Study Protocol**

Undecided - It is not yet known if there will be a plan to make this available

**Statistical Analysis Plan**

Undecided - It is not yet known if there will be a plan to make this available

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

**Clinical Study Report**

Undecided - It is not yet known if there will be a plan to make this available

**Analytic Code**

Undecided - It is not yet known if there will be a plan to make this available

**Data Dictionary**

Undecided - It is not yet known if there will be a plan to make this available